TY - ADVS
T1 - Case Study: Immunomodulatory Mechanism and Antimyeloma Effect of Daratumumab
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Tuesday, April 13, 2021 Patients with multiple myeloma and plasma cell leukemia (PCL) transformation tend to have a poor prognosis due to a high level of resistance to conventional therapy.
PY - 2021/4/13
Y1 - 2021/4/13
N2 - Patients with multiple myeloma and plasma cell leukemia (PCL) transformation tend to have a poor prognosis due to a high level of resistance to conventional therapy. A recent case study, presented by Yu Wu, MD, PhD, and colleagues of the Sichuan University in Chengdu, China, featured a 42-year-old man with resistant multiple myeloma who had PCL transformation and was successfully treated with daratumumab. The patient experienced complete remission followed by autologous hematopoietic stem cell transplantation (auto-HSCT). The details of this case presentation were published in Therapeutic Advances in Hematology.
AB - Patients with multiple myeloma and plasma cell leukemia (PCL) transformation tend to have a poor prognosis due to a high level of resistance to conventional therapy. A recent case study, presented by Yu Wu, MD, PhD, and colleagues of the Sichuan University in Chengdu, China, featured a 42-year-old man with resistant multiple myeloma who had PCL transformation and was successfully treated with daratumumab. The patient experienced complete remission followed by autologous hematopoietic stem cell transplantation (auto-HSCT). The details of this case presentation were published in Therapeutic Advances in Hematology.
UR - https://jnccn360.org/mm/medical-literature/case-study-immunomodulatory-mechanism-and-antimyeloma-effect-of-daratumumab/
M3 - Web publication/site
ER -